Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REaCT-TEMPO: Endocrine Therapy Dose-frequency Escalation in Breast Cancer
NCT05754528Phase 4Active, not recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Jul 2023
- Primary completion
- Nov 2025
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in breast cancer (2 arms), sponsored by Ottawa Hospital Research Institute. Primary endpoint: 1-year adherence with prescribed endocrine therapy. Started Jul 2023; status: active, not recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05754528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05754528.